Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M39.3Revenue (TTM) $M7.2Net Margin (%)-238.5Altman Z-Score-23.8
Enterprise Value $M36.3EPS (TTM) $-4.4Operating Margin %-253.9Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.3Pre-tax Margin (%)-238.4Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio1.3Cash flow > EarningsY
Price/Sales2.05-y EBITDA Growth Rate %16.9Current Ratio1.5Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-254.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M11.3ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with NBY

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

NBY is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


NBY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Najafi RaminCEO, 10% Owner 2015-08-20Buy480$11.75-70.3view
Pioneer Pharma (Singapore) Pte10% Owner 2015-03-03Buy103,600$15-76.73view
SIECZKAREK MARK MDirector 2015-03-03Buy6,667$15-76.73view
Najafi RaminChairman 2015-03-03Buy6,667$15-76.73view
Najafi RaminChairman 2014-12-12Buy2,000$16.25-78.52view
PAULSON THOMAS JCFO 2014-12-12Buy400$17-79.47view
Stroman David W.SVP, Ophthalmic Product Devt. 2014-12-12Buy400$16.5-78.85view
Najafi RaminChairman 2014-12-11Buy800$15-76.73view
PAULSON THOMAS JCFO 2014-12-09Buy400$16.75-79.16view
Najafi RaminChairman 2014-12-05Buy1,000$16.25-78.52view

Press Releases about NBY :

Quarterly/Annual Reports about NBY:

News about NBY:

Articles On GuruFocus.com
NovaBay Pharmaceuticals Inc. (NBY) Chairman Ramin Najafi buys 1,000 Shares Aug 28 2009 

More From Other Websites
NOVABAY PHARMACEUTICALS, INC. Financials Aug 19 2016
Dry Eye: A Growing Problem in an Aging Population Aug 15 2016
NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 Aug 12 2016
NovaBay Pharmaceuticals Reports 2016 Second Quarter Financial Results Aug 11 2016
NOVABAY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Aug 11 2016
NovaBay Pharmaceuticals Reports 2016 Second Quarter Financial Results Aug 11 2016
NovaBay Pharmaceuticals to Hold Second Quarter 2016 Conference Call on August 11 Aug 04 2016
NovaBay Pharmaceuticals to Hold Second Quarter 2016 Conference Call on August 11 Aug 04 2016
NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 02 2016
NovaBay Pharmaceuticals Completes $11.8 Million Private Placement Aug 02 2016
NovaBay Pharmaceuticals Completes $11.8 Million Private Placement Aug 02 2016
NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Entry into a Material Definitive... Jul 15 2016
New Treatments for Contact Lens Intolerance On The Rise Jun 28 2016
NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek President and Chief Executive Officer Jun 13 2016
NovaBay Pharmaceuticals Appoints Mark M. Sieczkarek President and Chief Executive Officer Jun 13 2016
NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... May 27 2016
NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q1, 2016 By the Numbers May 18 2016
NovaBay Pharmaceuticals Reports 2016 First Quarter Financial Results May 12 2016
NOVABAY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 12 2016
NovaBay Pharmaceuticals Reports 2016 First Quarter Financial Results May 12 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)